The present invention provides a process for preparing a heterocyclic aldehyde by oxidizing a heterocyclic alcohol with high selectivity and high yield. Specifically, the heterocyclic aldehyde is prepared by reacting a heterocyclic compound having at least one hydroxymethyl group bonded to a carbon atom of a heterocyclic ring with a hypohalogenous acid salt in the presence of a base to oxidize the hydroxymethyl group, wherein reaction is conducted in the co-presence of a 2,2,6,6-tetramethylpiperidine-1-oxyl derivative having at least two 2,2,6,6-tetramethylpiperidine-1-oxyl-4-yl groups.
N-aryl-1-amino indoles was established by the photoinduced N–N coupling reaction. This protocol is by treatment of o-nitrobenzyl alcohols and indolines in the presence of TEAI and acetic acid with a 24 W ultraviolet (UV) light-emitting diode (LED) (385–405 nm) irradiation. The products bearing an aldehyde group can be further transformed to fluorescent probes based on Rhodamine 6G derivative 11, which shows
通过光诱导N-N偶联反应建立了一种合成N-芳基-1-氨基吲哚的新方法。该协议是在 TEAI 和乙酸存在下用 24 W 紫外 (UV) 发光二极管 (LED) (385–405 nm) 照射处理邻硝基苄醇和二氢吲哚。带有醛基的产物可以进一步转化为基于罗丹明 6G 衍生物11 的荧光探针,显示出对 Fe 3+的高度特异性和灵敏度。
Bicyclic And Tricyclic Compounds As KAT II Inhibitors
申请人:Claffey Michelle M.
公开号:US20100324043A1
公开(公告)日:2010-12-23
Compounds of Formula X:
wherein A, X, Y, Z, R
5
, R
6a
, and R
6b
are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.